Roivant Sciences, a global healthcare company, raised $1.1 billion in equity funding.
The round was led by the SoftBank Vision Fund, with participation from existing shareholders including the Dexxon investor group.
The company intends to use the funds to accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry.
Led by Vivek Ramaswamy, Founder and CEO, Roivant focuses on developing and commercializing novel therapies through wholly- or majority-owned subsidiary companies. These include:
– Axovant (neurology),
– Myovant (women’s health and endocrine diseases),
– Dermavant (dermatology),
– Enzyvant (rare diseases), and
– Urovant (urology).
Datavant, a new technology-focused subsidiary, will be the first company in the Roivant family to operate outside of traditional biopharmaceutical development. It aims to dissolve barriers between siloed healthcare datasets in order to unlock novel insights and reduce the time and cost of delivering innovative medicines to patients.
The company has offices in Basel, Switzerland, New York, NY, Durham, NC, San Francisco, CA, Brisbane, CA, and Cambridge, MA.